FilingReader Intelligence
Alphamab Oncology's JSKN003 gets US orphan drug status
July 29, 2025 at 12:19 AM UTC•By FilingReader AI
Alphamab Oncology's JSKN003 has received Orphan Drug Designation from the U.S. FDA for treating gastric cancer and gastroesophageal junction cancer.
The designation provides benefits including potential funding, tax credits, fee waivers, accelerated review, and seven years of market exclusivity upon approval.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:9966•Hong Kong Exchange
News Alerts
Get instant email alerts when Alphamab Oncology publishes news
Free account required • Unsubscribe anytime